

UNITED STATES OF AMERICA

## **DECLARATION** FOR PATENT APPLICATION

111 END			
As a below	named inventor(s), I/We he	reby declare that:	
	My/Our residence(s), pos I/We verily believe I am/ and for which a patent is	we are the ondinal, first a	ifizenship(s) are as stated below my name(s). and sole/joint inventor(s) of the subject matter which is claime ntitled:
		For Quantitatively De	etermining Specific Groups Constituting Molecular Weight Heparins
	and the specification of w (check опе)	✓ was filed on I     and was ame     ✓ was describe	ereto (Aventis Docket No.FRAV2002/0026 US CIP)  March 25, 2004 as U.S. Application Number 10/808,791  nded on (if applicable), d and claimed in PCT Int'l Application Number filed on as amended under PCT Article 19 on (if any).
	monutary the claims as an	ty to disclose to the U.S.	Patent and Trademark Office all Information known to make the
	least one other country of the application on which	her than the United States priority is claimed I/We	tle 35, United States Code §119(a)-(d) or 365 (b) of any foreig 365(a) of any PCT international application which designated as of America, listed below and having a filing date before that dhave also identified below any foreign application for patent of of the application on which priority is claimed:
Foreign Priority:	02 11724 Number	France Country	23/September/2002 Day/Month/Year Filed
Prior Foreign Appln(s):	Number	Country	Day/Month/Year Filed
$\boxtimes$	I/We hereby claim the application(s) listed below	benefit under Title 35, U w:	nited States Code §119(e) of any United States Provisiona
	60/422,482 Number	October 31, 2002 Filing Date	_
×	I/We hereby claim the application(s) or internation matter of each of the claim provided by the first parainformation which is matter became available between this application.	benefit under Title 35, onal application designati ns of this application is no agraph of Title 35, United erial to patentability as d n the filing date of the prio	United States Code §120 or 365(c) of any United States ng the United States listed below and, insofar as the subject disclosed in the prior United States application in the manned States Code §112, I/We acknowledge the duty to disclose efined in Title 37, Code of Federal Regulations §1.56 which application and the national or PCT International filing date or
,	10/665,872 Application Serial No.	September 18, 2003 Filling Date	Pending Status (Patented, Pending)
and the like	so made are punishable by	urvier uiau uiese stateme Tine or imprisonment or	nowledge are true and that all statements made on information nts were made with the knowledge that willful false statements both, under Title 18, United States code s1001, and that such on or any patent issued thereon.
Inventors(s):	Additional names	and signatures are attach	ed.
1. Full name:	Christian VISKOV		2. Full name: Pierre MOURIER
Signature:		skov	Signature: trene Mourier
Date:	04/14/04		Date: 04/16/04
	zenship: <b>France</b> is <b>Orangis, France</b> (City and State/City and Cou	mtov only)	Country of Cilizenship: Francé Residence: Charenton LePont, France
P. O. Address	3 rue du Bearn	nuy only)	(City and State/City and Country only)
	91130 Ris Orangis (Fra	ance)	P. O. Address: 1 rue Etienne Mehul 94220 Charenton LePont (France)
			Same appreciately reconditions

ignature:	Signature
ate:	Signature:
ountry of Citizenship;	Date:Country of Citizenship:
esidence:	Residence:
esidence:(City and State/City and Country only)	Residence: (City and State/City and Country only
. O. Address:	P. O. Address:
. Full name:	
5. Full name:	<b>6.</b> Full name:
ignature:	6. Full name:
Signature:	G. Full name: Signature: Date:
Signature: Date: Country of Citizenship:	6. Full name:
ignature:ate:ate:ate:ate:ate:ate:ate:ate:ate:ate:	6. Full name:
ignature:ate:	6. Full name:

## BEST AVAILABLE COPY

Customer No.: 005487

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 P.O. Box 6800 Mail Code D-303A Bridgewater, NJ 08807-0800 Telephone (908) 231-2387 Telefax (908) 231-2626

Aventis Docket No. FRAV2002-0026 US CIP

31, 2004

Aventis Docket No. FRAV2002/0026 US CIP

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Christian VISKOV, et al

Examiner:

Not Yet Assigned

Serial No.: 10/808,791

Group Art Unit:

Not Yet Assigned

Filed:

March 25, 2004

Title:

Method For Quantitatively Determining Specific Groups Constituting Heparins Or

Low Molecular Weight Heparins

## POWER OF ATTORNEY FOR PATENT APPLICATION

Mail Stop Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

ROUSSEAU Pierrick , an Authorized Signatory of Aventis Pharma S.A., Assignee of the above-identified Application, hereby appoint the attorneys and/or agents associated with the Customer No.(s) provided below as attorneys and/or agents with full power to prosecute this application on behalf of Assignee and to transact all of Assignee's business in connection with the above-identified Application in the Patent and Trademark Office:

Customer No.: 005487

Effective Date:

March 25, 2004

By:

ROUSSEAU Pierrick

Title:

Executive

Date:

May 5, 2004

Customer No.: 005487

Charlotte L. Barney, Reg. No. 35,060

Aventis Pharmaceuticals Inc.

Patent Department

Route #202-206 / P.O. Box 6800 Bridgewater, New Jersey 08807-0800 Telephone (908) 231-2387

Telefax

(908) 231-2626